Par Pharmaceutical dexmedetomidine injection recalled for particulate matter contamination
What this means
Par Pharmaceutical is recalling two lots of dexmedetomidine HCl injection used in hospitals for patient sedation. The vials contain unwanted particles of cellulose or stopper material that could cause serious blood vessel blockages or clotting if injected into patients. No patient injuries have been reported so far.
- If you work in a hospital pharmacy or ICU: immediately stop using lots 87558 and 88802 and remove them from shelves.
- Contact your pharmaceutical supplier or Inmar at 1-833-599-3197 (Mon–Fri, 9 a.m.–5 p.m. ET) to arrange return of affected inventory.
- Report any patient exposures or adverse events to FDA MedWatch at www.fda.gov/medwatch or 1-800-332-1088.
Product photos
The agency's original wording
ROCHESTER, MI– September 18, 2026 –Par Health is voluntarily recalling two lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection 400 mcg/100 mL (4 mcg/mL) to the hospital level. The product is being recalled due to the presence of particulate matter identified as cellulose or stopper materia
Official notice
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/par-health-issues-voluntary-nationwide-recall-two-lots-dexmedetomidine-hcl-09-sodium-chlorideWant us to check the next one for you?
We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering parents — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.